HKD 3.58
(-0.56%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 51.33 Million USD | -1.99% |
2022 | 52.37 Million USD | 72.51% |
2021 | 30.35 Million USD | -85.14% |
2020 | 204.36 Million USD | 177.01% |
2019 | 73.77 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 52.39 Million USD | 0.0% |
2024 Q1 | 52.39 Million USD | 2.08% |
2023 FY | 51.33 Million USD | -1.99% |
2023 Q2 | 54.99 Million USD | 0.0% |
2023 Q1 | 54.99 Million USD | 5.01% |
2023 Q4 | 51.33 Million USD | 0.0% |
2023 Q3 | 51.33 Million USD | -6.67% |
2022 Q2 | 39.37 Million USD | 0.0% |
2022 Q1 | 39.37 Million USD | 29.69% |
2022 FY | 52.37 Million USD | 72.51% |
2022 Q4 | 52.37 Million USD | 0.0% |
2022 Q3 | 52.37 Million USD | 33.01% |
2021 Q3 | 331.15 Million USD | 0.0% |
2021 FY | 30.35 Million USD | -85.14% |
2021 Q4 | 30.35 Million USD | -90.83% |
2021 Q1 | - USD | -100.0% |
2020 Q4 | 204.36 Million USD | 0.0% |
2020 FY | 204.36 Million USD | 177.01% |
2019 FY | 73.77 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | 66.411% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 99.273% |